4DMedical Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andreas Fouras
- Full Time Employees
- 181
- Sector
- Technology services
- Industry
- Information technology services
- Address
- Melbourne Connect Carlton VIC Australia 3053
- IPO Date
- Aug 7, 2020
- Website
- 4dmedical.com
- Similar Companies
- Business
- 4DMedical Limited (ASX:4DX) develops and commercializes advanced four-dimensional lung imaging technologies for the diagnosis and management of respiratory diseases. The company offers XV Lung Ventilation Analysis Software (XV LVAS), a FDA-cleared SaaS platform that uses proprietary XV Technology to quantify regional lung ventilation from standard X-ray fluoroscopy images; CT LVAS, its computed tomography counterpart for structural and functional lung analysis; the XV Scanner, the world's first dedicated zero-contrast lung function scanner; and a suite of AI-powered lung and cardiothoracic diagnostic tools acquired through Imbio, including solutions for emphysema quantification, lung fibrosis detection, lung cancer screening, and coronary plaque analysis. These products operate on existing hospital imaging infrastructure, providing clinicians with quantitative airflow, perfusion, and structural data visualized as heat maps and reports to support conditions such as COPD, asthma, cystic fibrosis, interstitial lung disease, and lung cancer. Founded in 2012 and headquartered in Carlton, Victoria, Australia, with additional operations in Woodland Hills, California, USA, 4DMedical targets healthcare providers, veterans' health programs, and research institutions across Australia, the United States, and select international markets. The company originated from Monash University research on XV Technology, initially conceived in 2005, and focuses on pulmonary medicine segments including primary care radiology, companion diagnostics, and federal health screening initiatives. It employs approximately 145 staff and collaborates with leading institutions and partners like Philips for integration into critical care systems. In December 2023, 4DMedical completed the US$25 million acquisition of U.S.-based Imbio, adding AI-driven CT analysis tools and accelerating U.S. commercialization, particularly for veterans exposed to toxic burn pits under the PACT Act; the deal included a A$35 million equity placement and contingent earnouts tied to revenue milestones. The company signed a Memorandum of Understanding with Philips in late 2023 to integrate its imaging solutions into VA and DoD systems, expanding access via Philips' established partnerships covering over 50% of VA clinics. Fiscal 2024 saw operating revenue surge 422% to A$3.8 million, bolstered by Medical Research Future Fund grants, state funding, and R&D tax incentives, positioning 4DMedical for profitability through combined structural-functional lung diagnostics.
Company News
4DMedical erhält TGA-Zulassung für CT:VQ™ und bringt damit kontrastmittelfreie Ventilations-/Perfusionsbildgebung nach Australien
4DMedical Limited (FDMDF) M&A Call Transcript
4DMedical Limited (FDMDF) Discusses Clinical Use of CT:VQ in Patient Selection for Lung Volume Reduction Surgery Transcript
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
Avec l'obtention du marquage CE pour CT:VQ™, 4DMedical est prêt pour sa mise sur le marché dans l'Union européenne
4DMedical recibe la marca CE para CT:VQ™, lo que permitirá su lanzamiento comercial en toda la Unión Europea
4DMedical erhält CE-Kennzeichnung für CT:VQ™ und ermöglicht damit die Markteinführung in der gesamten Europäischen Union
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
Andreas Fouras Buys 1,850,914 Shares of 4DMedical (ASX:4DX) Stock
Andreas Fouras Sells 263,157 Shares of 4DMedical (ASX:4DX) Stock
Julian Sutton Sells 2,266,666 Shares of 4DMedical (ASX:4DX) Stock
Julian Sutton Acquires 4,266,666 Shares of 4DMedical (ASX:4DX) Stock
4DMedical Limited (FDMDF) Discusses Imaging Technology Portfolio and Market Positioning in Cardio-Pulmonary Diagnostics Transcript
4DMedical Limited (FDMDF) Discusses Expansion of Distribution Agreement for CT:VQ Non-Contrast Lung Imaging Solution Transcript
4DMedical Limited - Special Call
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology